Summary
We developed the TREAT assay: an rAAV infectious titration process using TESSA® to express the adenovirus helper genes and AAV Rep.
As TESSA® is a self-repressed adenovirus, its application for rAAV titration should provide a safer alternative to the use of wildtype adenoviruses.
TREAT enables amplification of the rAAV genome in various target cells for sensitive detection via qPCR and determination of rAAV infectious titre using the TCID50 assay.
TREAT assay is a qualified assay following GMP viral vectors analytical requirements for accurate rAAV titration suitable for research and clinical applications.
Contact business@oxgene.com for more information.